Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?

One of the most successful investors ever really likes this up-and-coming biotech stock.

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?

Published August 25, 2026 · Category: Finance

Overview

Imagine running a fund for 30 years, including during the aftermath of the dot-com bubble bursting and the financial crisis of 2008, without a single losing year. If you're Stanley Druckenmiller, no imagination is required. He achieved this feat for Duquesne Capital Management between 1981 and 2010, delivering an average annual return of roughly 30%.

Druckenmiller no longer runs Duquesne Capital Management after deciding to close shop in 2010. However, he does manage the Duquesne Family Office, a private investment firm that handles his and his family's money.

Details

With such an impressive track record, many investors understandably pay attention to which stocks Druckenmiller likes. And the billionaire continues to load up on Revolution Medicines (NASDAQ: RVMD), a biotech stock for which analysts have only modest near-term growth expectations. Does Druckenmiller know something that Wall Street doesn't?

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.